Systemic lupus erythematosus: Extent and patterns of off-label use of rituximab for SLE.
Where this comes from
- Record sourced from PubMed, PMID 27872475.
- Also identified by DOI 10.1038/nrrheum.2016.191 and PMC identifier 5476200.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Despite conflicting evidence from clinical trials, rituximab continues to be used off-label in the treatment of systemic lupus erythematosus (SLE). A new study has now investigated the use of this drug for SLE in Europe, including indications for use and patient characteristics.